Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on immune responses to schistosome antigens among the offspring: results of a randomised, placebo-controlled trial

Table 3 Association between maternal or cord blood antibody levels and maternal infection intensity at enrolment

		Maternal Antibodies to SWA	Maternal Antibodies to SEA	Cord blood antibodies to SWA	Cord blood antibodies to SEA
IgG1	Placebo	0.45 (< 0.001)	-0.09 (0.314)	0.51 (< 0.001)	-0.15 (0.105)
	Praziquantel	0.53 (< 0.001)	-0.06 (0.517)	0.53 (< 0.001)	-0.18 (0.062)
IgG2	Placebo	0.22 (0.013)	-0.21 (0.019)	0.32 (< 0.001)	-0.20 (0.039)
	Praziquantel	0.39 (< 0.001)	-0.15 (0.099	0.45 (< 0.001)	-0.13 (0.192)
IgG3	Placebo	-0.10 (0.244)	-0.24 (0.008)	-0.10 (0.31)	-0.33 (< 0.001)
	Praziquantel	0.43 (< 0.001)	0.06 (0.532)	0.33 (< 0.001)	0.04 (0.674)
IgG4	Placebo	0.24 (0.008)	0.40 (< 0.001)	0.23 (0.016)	0.35 (< 0.001)
		0.31 (0.0003)	0.38 (< 0.001)	0.23 (0.019)	0.44 (< 0.001)
IgE	Placebo	0.29 (0.0009)	-0.17 (0.062)		0.02 (0.798)
	Praziquantel	0.21 (0.017)	-0.02 (0.855)		-0.03 (0.732)

Shown are Spearman's correlation coefficients (p-values); For maternal antibodies N = 125 in placebo group and 127 in praziquantel group. For cord blood antibodies N = 110 in placebo group and 102 in the praziquantel group.

ISSN: 1471-2334